Key result
Secondary cutaneous angiosarcoma shares similar survival with de novo cases while rising to ~51% of diagnoses.
Why the study?
Cutaneous angiosarcoma is a rare, poorly established malignant neoplasm with a dismal prognosis, and its treatment remains controversial.
Cohort (n=872)
Yes
Secondary and de novo cutaneous angiosarcomas share similar survival outcomes, and surgical resection remains an important prognostic factor for improved overall survival in both groups.
May inform equivalent prognostic counseling; leaves open drivers of rising secondary proportion.
BACKGROUND: Cutaneous angiosarcoma (cAS) is a rare and not well-established malignant neoplasm characterized by dismal prognosis. Treatment for cAS remains controversial. OBJECTIVE: From 1975 to 2016, a total of 872 patients with cAS (379 secondary cAS [s-cAS] patients and 493 de novo cAS [dn-cAS]) patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: Survival analyses were performed utilizing Kaplan-Meier curves and Cox proportional hazards regression models. RESULTS: Both the number of s-cAS patients and dn-cAS patients climbed steadily over 42 years. There is a gradual increase in the proportion of s-cAS among whole cAS patients for each interval, ranging from 0% to 51.2%.Taking into account a combination of Kaplan-Meier and Cox regression methods, the survival of s-cAS is similar to dn-cAS. On multivariate analysis, older age, greater tumor size, primary site located at lower extremity, advanced stage, and no surgery were independent prognostic factors of decreased overall survival (OS) in both the s-cAS and dn-cAS groups. CONCLUSION: Apparent increase in the number of s-cAS patients requires further attention. Surgery is still recommended for the treatment of both s-cAS and dn-cAS patients, and the requirement for treatment improvement is imperative.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2023) conducted a cohort in Cutaneous angiosarcoma (n=872). Secondary cutaneous angiosarcoma vs. De novo cutaneous angiosarcoma was evaluated on Overall survival. Secondary cutaneous angiosarcoma showed similar overall survival to de novo cases, while its proportion among all cutaneous angiosarcoma patients increased steadily over 42 years from 0% to 51.2%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: